BLAINTRATRACHEALSUSPENSION
Approved
Nov 1999
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
7
Data completeness
4/8 — Partial
CUROSURF (poractant alfa) by Chiesi is surfactant activity [moa]. First approved in 1999.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CUROSURF (poractant alfa) is an intratracheal surfactant suspension approved in 1999 for respiratory distress syndrome in neonates. It works by restoring surfactant activity in the lungs, reducing surface tension and improving gas exchange. This biologic replacement therapy is administered directly into the trachea of premature infants.
LOE Approaching
Product is entering loss-of-exclusivity phase with moderate competitive pressure (30%), signaling potential team restructuring and shift toward defensive market strategies.
Mechanism of Action
Surfactant Activity
Pharmacologic Class:
Surfactant
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (7)
A Study in Preterm Neonates With Respiratory Distress Syndrome (RDS) Comparing CUROSURF® Administration Through Less Invasive Surfactant Administration (LISA) and Conventional Administration
Started May 2021
33 enrolled
Respiratory Distress Syndrome (RDS)
Poractant Alfa (Curosurf®)) -- Effect in Adult Patients Diagnosed With 2019 Novel Coronavirus (SARS-COV-19; (Covid-19)) Acute Respiratory Distress Syndrome (ARDS)
Started Jan 2021
22 enrolled
Acute Respiratory Distress Syndrome
Efficacy and Safety of Curosurf® in Patients Invasively Ventilated for Severe Bronchiolitis Under 12 Months of Age
Started Jan 2019
9 enrolled
Bronchiolitis, Viral
A Study To InvestigateThe Safety, Tolerability And Efficacy Of Nebulised Curosurf® In Preterm Neonates With Respiratory Distress Syndrome (RDS)
Started Aug 2017
166 enrolled
Neonatal Respiratory Distress Syndrome
A Double Blind, Randomized, Controlled Study to Evaluate CHF 5633 (Synthetic Surfactant) and Poractant Alfa in Neonates With Respiratory Distress Syndrome (RDS) (POC)
Started Jan 2016
123 enrolled
Respiratory Distress Syndrome, Newborn
Worked on CUROSURF at Chiesi? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.